Clinical Trials Browser

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Carcinoma, Adenoid Cystic

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Inflammatory Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Multiple Myeloma

Urinary Bladder Neoplasms

Breast Neoplasms

Breast Neoplasms

HR-positive,HER2-negative Breast Cancer

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Breast Neoplasms

Adenocarcinoma of the Esophagogastric Junction

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Lymphoma, Large B-Cell, Diffuse

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Down Syndrome, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Neoadjuvant Operable Breast Cancer

Breast Neoplasms, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms

Clinical Trials

NeoSACT

TARMAC

EIC-SNACC

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

PELICAN

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

ARIADNE

FASCINATE-N

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

NeoHunter

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

GAIN INST

SAFIR02_Breast

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

SPRING

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

NeoTENNIS

QUEEN-Neo

KEYPARTNER

GAMEC-II

POLO

SMA-BC-002

MEMORI

ANZAC

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

HIFU

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

DDP

Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

NeoMET

Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

NeoPAL

TARMAC

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer